Detail akcie Aethlon Medical Rg online

Business Summary: Aethlon Medical, Inc. is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. The Hemopurifier, in pre-clinical studies, has demonstrated the removal of harmful exosomes from biological fluids, utilizing its lectin-based technology. The Hemopurifier is a United States Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption application related to the treatment of life-threatening viruses that are not addressed with approved therapies.
Financial Summary: BRIEF: For the fiscal year ended 31 March 2025, Aethlon Medical Inc revenues was not reported. Net loss applicable to common stockholders increased 10% to $13.4M. Higher net loss reflects Interest Income decrease of 30% to $298K (income), Rental Expense increase of less than 1% to $422K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$38.87 to -$8.58.